Down's syndrome - Clinical trial details 

Genetically determined brain abnormalities in Down's syndrome - towards a treatment: Down's syndrome Lithium Trial

Recruitment status:
Not recruiting
Primary Sponsor:
King's College London (UK)
Recruitment countries:
Health condition studied:
Down's syndrome
Link to the clinical trial website

About the trial

Lithium carbonate (Camcolit®), 250mg oral tablets versus placebo.

Titration phase: dose adjusted to achieve therapeutic plasma level of 0.4 - 1.0 mmol/l
Maintenance phase: twice daily dosing for 4 weeks on therapeutic lithium carbonate dose
Titration Phase: Dose adjusted to achieve therapeutic plasma level of 0.4-1.0mmol/L
Maintenance Phase: Twice daily dosing for 4 weeks on therapeutic lithium carbonate dose

Total duration of treatment is around 8 weeks; follow-up will be as appropriate if patients have any side-efects on Lithium, otherwise patient involvement ends when they come off the medication. Likewise for placebo group.
Key inclusion and exclusion criteria:
  • Inclusion criteria: 1. Individuals with Down's syndrome
    2. Over the age of 18 years, either sex
    3. Able to provide informed consent for themselves or have a representative to provide proxy consent on their behalf if they lack capacity
    4. Able to communicate with the investigator and to comply with requirements of the study
    5. Has carer support
  • Exclusion criteria: 1. Individuals with contraindications to lithium treatment
    2. Individuals with contraindications to undergoing a magnetic resonance scan
    3. Non-compliance with taking of the tablets between baseline and the final assessment
    4. Treatment with lithium within the last 6 months
    5. Evidence of dementia
    6. Evidence of renal, thyroid or cardiac disease that would contraindicate taking lithium
    7. Pregnancy
  • Age minimum: 
  • Age maximum: 
  • Gender: 
Primary outcomes:
Brain myo-inositol concentrations (dorsolateral prefrontal cortex [DLPFC] and hippocampus) measured by 1H magnetic resonance spectroscopy (MRS) at baseline and after 4 weeks maintenance lithium treatment at therapeutic dose.
Secondary outcomes:
1. Blood biomarkers which have been implicated in the development of Alzheimer's Disease:
1.1. Isolation of genomic DNA for studies of genotype in relation to response including the Tau haplotype, Intron 7 repeat of APP, and ApoE4
1.2. Abeta1-40, Abeta1-42 base fragments and other amyloid species
1.3. Markers of amyloid oxidative stress e.g. isoprostane and other members
1.4. Markers of systemic inflammation e.g. IL-6, TNF-alpha and other inflammatory markers
1.5. Other markers of APP processing e.g. BACE
2. Cognitive measures:
2.1. British Picture Vocabulary Scale (BPVS) at baseline
2.2. Cambridge Examination for mental disorders of the elderly revised (CAMDEX-R) section on Cognitive Examination (CAMCOG) after 4 weeks maintenance lithium treatment at therapeutic dose
Target sample size:
Study type:
Study design:
Single centre randomised single-blind placebo controlled trial

Technical details

Scientific title:
Genetically determined brain abnormalities in Down's syndrome - towards a treatment: A randomised, single-blind, placebo controlled trial of lithium carbonate in Down's syndrome
Sources of monetary support:
Baily Thomas Charitable Fund (UK) (ref: 2215/1)
Secondary sponsors:
Main ID:
Secondary ID:
Sponsor ID: RAA08-015; EUDRACT Number: 2008-008342-20
Date of registration:
Date of first enrollment:
Jun 1 2009
Last refreshed:
14 July 2014


Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record

Back to clinical trials list